Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2901-2908

  Ducreux, Michel ^a   Ychou, Marc ^a   Seitz, Jean François ^a   Bonnay, Marc ^a   Bexon, Alice ^a   Armand, Jean Pierre ^a   Mahjoubi, Monder ^a   Méry Mignard, Dominique ^a   Rougier, Philippe ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0032833697     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2901     Document Type: Article

References (39)

1. Kunimoto T, Nitta K, Kanaka T, et al: Antitumor activity of 7-ethyl-10 (4 -(1-piperidino)-1-piperidino)-1-carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987
2. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638, 1989
3. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
4. Eng WK, Faucette L, Johnson RK, et al: Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34:755-760, 1988
5. Liu LF: DNA topoisomerases: Enzymes that catalyse the breaking and rejoining of DNA. CRC Crit Rev Biochem 15:1-24, 1983
6. Wang JC: DNA Topoisomerases. Annu Rev Biochem 54:665-697, 1985
7. Gottlieb JA, Guarino AM, Call JB, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461-470, 1970
8. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
9. Rothenberg ML, Eckert JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
10. Conti JA, Kemeny NE, Salz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
11. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
12. Pitot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910-2919, 1997
13. Cunningham D, Pyrhönen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:9138, 1413-1418, 1998
14. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
15. Cohen AM, Minsky BD, Schilsky RL: Colon cancer, in Devita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 929-967
16. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330:1136-1142, 1994
17. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 10:904-911, 1992
18. Scheitauer W, Rosen H, Kornek GV, et al: Randomized comparison of combination chemotherapy plus supportive care or supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752-755, 1993
19. De Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
20. Aranda E, Diaz-Rubio E, Cervantes A, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 9:727-731, 1998
21. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995
22. Ardalan B, Chua L, Tien E, et al: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9:625-630, 1991
23. Sobrero AF, Aschele C, Bertino Jr: Fluorouracil in colorectal cancer: A tale of two drugs - Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
24. Hansen R, Quebban E, Ausman R, et al: Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: Results in 91 patients. J Surg Oncol 40:177-181, 1989
25. Findlay M, Hill A, Cunningham D, et al: Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer. Ann Oncol 5:239-243, 1994
26. Jäger E, Klein O, Wächter B, et al: High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: Results of a phase II study. Eur J Cancer 31A:1717-1717, 1995
27. Izzo J, Fandi A, Villalobos W, et al: Low-dose protracted continuous 5-fluorouracil infusion in solid tumors. J Infus Chemother 4:135-139, 1994
28. Weh HJ, Wilke HJ, Dielamm J, et al: Weekly therapy with folinic acid (FA) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 5:233-237, 1994
29. Rothenberg ML, Hainsworth JD, Rosen L, et al: Phase II study of irinotecan (CPT-11) 250 mg/m2 given every other week in previously treated colorectal cancer patients. Proc Am Soc Clin Oncol 17:1092, 1998 (abstr)
30. Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer 47:207-214, 1981
31. Abigerges D, Chabot GG, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13, 210-221, 1995
32. Barilero I, Gandia D, Armand JP, et al: Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: Application to plasma pharmacokinetic studies in cancer patients J Chromatogr 575:275-80, 1992
33. Benhammouda A, Bastian G, Rixe O, et al: A phase I and pharmacokinetic study of CPT-11 and 5 FU combination. Proc Am Soc Clin Oncol 16:202:710, 1997 (abstr)
34. Saltz L, Kanowitz J, Kemeny N, et al: Phase I clinical and pharmacokinetic study of irinotecan, 5FU and leucovorin in patients with advanced solid tumors. J Clin Oncol 14:2959-2967, 1996
35. Rothenberg ML, Pazdur R, Rowinsky EK, et al: A phase II multicenter of alternating cycles of irinotecan and 5FU/LV in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 16:944, 1997 (abstr)
36. Van Cutsem E, Pozzo C, Starkhammar H, et al: A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol 9:1199-1204, 1998
37. Sastrey J, Paz-Ares L, Diaz-Rubio E, et al: Phase I dose finding study of irinotecan (CPT-11) over a short IV infusion combined with a fixed dose of fluorouracil (5FU) protracted continuous IV infusion in patients with advanced solid tumors. Eur J Cancer 33:1141, 1997 (suppl 8) (abstr)
38. Vanhoefer U, Harstrick A, Müller C, et al: Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 17:907-913, 1999
39. Chabot GG, Abigerges D, Catimel G, et al: Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141-151, 1995